Pharmaceuticals News and Research

RSS

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris.

19 Mar 2014

Celgene reiterates commitment to increase awareness and understanding of pancreatic cancer

With pancreatic cancer poised to become the third leading cause of cancer death in Europe, Celgene International Sàrl, a subsidiary of Celgene Corporation, has today reiterated its commitment to patients and their families with the announcement that it will focus significant resources to increase awareness and understanding of the disease.

19 Mar 2014

PAREXEL International expands global Clinical Logistics Services capabilities

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the expansion of its global Clinical Logistics Services (CLS) capabilities. A new, state-of-the-art distribution center in Singapore and the recent expansion of the Company's facilities in Billerica, Mass., will help PAREXEL more effectively manage clients' global clinical trial supply requirements.

From Parexel 19 Mar 2014

Cannabis and NTRR poised to outpace expansion of global smartphone market

Cannabis is among the fastest-growing markets in the U.S., poised to outpace the expansion of the global smartphone market—and Neutra Corp. (OTCBB: NTRR) is readying a diverse product line to capitalize on that growth.

19 Mar 2014

New invention helps body generate new bone which is as strong as original

Periodontitis can cause teeth to come loose. Mandibular cancer can disfigure a face. With the aid of artificial, foam-rubber-shaped scaffolding, the body can be helped to repair the damage by itself.

19 Mar 2014

Alberta collaborates with Janssen to advance early-stage technologies related to diabetes

The Alberta Diabetes Institute at the University of Alberta has announced a new collaboration with Janssen Inc. in Canada to advance early-stage technologies related to Type I and Type II diabetes. Janssen is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

19 Mar 2014

Scientists build tiny "molecular drill bits" that kill bacteria by bursting through their protective cell walls

In response to drug-resistant "superbugs" that send millions of people to hospitals around the world, scientists are building tiny, "molecular drill bits" that kill bacteria by bursting through their protective cell walls.

18 Mar 2014

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.

18 Mar 2014

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination.

18 Mar 2014

Findings support development of cysteine protease inhibitors as new drug target for AD

A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-Aβ peptides linked to Alzheimer's disease (AD). Moreover, the candidate inhibitor drug has been shown to be safe in humans.

18 Mar 2014

New research commissioned to create infection control strategy for AMR and antibiotic usage

It is the health system’s nightmare, bubbling just below the surface of our hospitals. Infections are becoming more and more resistant to antibiotics, while secondary infection rates during hospital stays continue to rise.

18 Mar 2014

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy".

18 Mar 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

Researchers develop therapy to attack cervical cancer tumors

One of the most promising technologies for the treatment of various cancers is nanotechnology, creating drugs that directly attack the cancer cells without damaging other tissues' development.

17 Mar 2014

Chindex revenue increases 12% to $48.8M in fourth quarter 2013

Chindex International, Inc., an American healthcare company providing premium quality healthcare services in China through the operations of United Family Healthcare ("UFH"), a network of private primary care hospitals and affiliated ambulatory clinics, today announced financial results for the fourth quarter and full year of 2013 ended December 31, 2013.

17 Mar 2014

Scientists develop new water purifier that could work with sunlight

Sunlight plus a common titanium pigment might be the secret recipe for ridding pharmaceuticals, pesticides and other potentially harmful pollutants from drinking water.

17 Mar 2014

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products.

17 Mar 2014

FDA grants Fast Track designation to Edison’s lead drug EPI-743

Edison Pharmaceuticals today announced that the United States Food and Drug Administration granted Fast Track designation to EPI-743, the company's lead drug, for the treatment of Friedreich's ataxia. EPI-743 is being developed for pediatric and adult mitochondrial disease, including Friedreich's ataxia.

17 Mar 2014

Researchers discover certain proteins in osteoclasts that may be used to destroy cardiovascular calcification

Cardiovascular calcification (deposits of minerals in heart valves and blood vessels) is a primary contributor to heart disease, the leading cause of death among both men and women in the United States according the Centers for Disease Control and Prevention (CDC).

17 Mar 2014

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

Pharmaceuticals News and Research

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Celgene reiterates commitment to increase awareness and understanding of pancreatic cancer

PAREXEL International expands global Clinical Logistics Services capabilities

Cannabis and NTRR poised to outpace expansion of global smartphone market

New invention helps body generate new bone which is as strong as original

Alberta collaborates with Janssen to advance early-stage technologies related to diabetes

Scientists build tiny "molecular drill bits" that kill bacteria by bursting through their protective cell walls

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Findings support development of cysteine protease inhibitors as new drug target for AD

New research commissioned to create infection control strategy for AMR and antibiotic usage

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Trovagene reports net loss of $1 million for fourth quarter 2013

Researchers develop therapy to attack cervical cancer tumors

Chindex revenue increases 12% to $48.8M in fourth quarter 2013

Scientists develop new water purifier that could work with sunlight

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

FDA grants Fast Track designation to Edison’s lead drug EPI-743

Researchers discover certain proteins in osteoclasts that may be used to destroy cardiovascular calcification

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring